9 September 2021 - NICE has today published final draft guidance which recommends tofacitinib (Xeljanz; Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.

The treatment is available for young people whose arthritis has not responded well enough to disease modifying anti-rheumatic drugs and only if:

• A tumour necrosis factor alfa inhibitor is not suitable or does not control the condition well enough
• Pfizer provides tofacitinib according to the commercial arrangement